DDInter667 DDInter1233
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloprolifer
Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma and is used off-label for the management of Cushing's syndrome.
Erlotinib {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Mitotane
Erlotinib {u} (Compound) causes {v} (Side Effect) Dyspepsia
Dyspepsia {u} (Side Effect) is caused by {v} (Compound) Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) Mitotane
Erlotinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) Mitotane
Erlotinib {u} (Compound) upregulates {v} (Gene) CTNND1
CTNND1 {u} (Gene) is downregulated by {v} (Compound) Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) Mitotane
Erlotinib {u} (Compound) upregulates {v} (Gene) CTNND1
CTNND1 {u} (Gene) is regulated by {v} (Gene) SERPINA6
SERPINA6 {u} (Gene) is bound by {v} (Compound) Mitotane
Erlotinib {u} (Compound) upregulates {v} (Gene) CTNND1
CTNND1 {u} (Gene) regulates {v} (Gene) AGR2
AGR2 {u} (Gene) is upregulated by {v} (Compound) Mitotane
Erlotinib {u} (Compound) upregulates {v} (Gene) CTNND1
CTNND1 {u} (Gene) regulates {v} (Gene) GJA1
GJA1 {u} (Gene) is downregulated by {v} (Compound) Mitotane
Erlotinib {u} (Compound) upregulates {v} (Gene) KIAA0196
KIAA0196 {u} (Gene) is regulated by {v} (Gene) ARNT2
ARNT2 {u} (Gene) is downregulated by {v} (Compound) Mitotane
Erlotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cannabidiol
Cannabidiol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) Mitotane
Erlotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxcarbazepine
Oxcarbazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorpheniramine
Chlorpheniramine {u} (Compound) resembles {v} (Compound) Mitotane
Erlotinib (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Mitotane (Compound)
Erlotinib (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Carbinoxamine (Compound) and Carbinoxamine (Compound) resembles Mitotane (Compound)
Erlotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Carbinoxamine (Compound) and Carbinoxamine (Compound) resembles Mitotane (Compound)
Erlotinib (Compound) upregulates CTNND1 (Gene) and CTNND1 (Gene) is downregulated by Carbinoxamine (Compound) and Carbinoxamine (Compound) resembles Mitotane (Compound)
Erlotinib (Compound) upregulates CTNND1 (Gene) and CTNND1 (Gene) is regulated by SERPINA6 (Gene) and SERPINA6 (Gene) is bound by Mitotane (Compound)
Erlotinib (Compound) upregulates CTNND1 (Gene) and CTNND1 (Gene) regulates AGR2 (Gene) and AGR2 (Gene) is upregulated by Mitotane (Compound)
Erlotinib (Compound) upregulates CTNND1 (Gene) and CTNND1 (Gene) regulates GJA1 (Gene) and GJA1 (Gene) is downregulated by Mitotane (Compound)
Erlotinib (Compound) upregulates KIAA0196 (Gene) and KIAA0196 (Gene) is regulated by ARNT2 (Gene) and ARNT2 (Gene) is downregulated by Mitotane (Compound)
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mitotane (Compound)
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine (Compound) resembles Mitotane (Compound)